Ruth Vera García-rekin lankidetzan egindako argitalpenak (12)

2024

  1. Oleuropein-driven reprogramming of the myeloid cell compartment to sensitise tumours to PD-1/PD-L1 blockade strategies

    British Journal of Cancer, Vol. 130, Núm. 5, pp. 869-879

  2. PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets

    EMBO Molecular Medicine, Vol. 16, Núm. 8, pp. 1791-1816

2023

  1. Plasma fractalkine contributes to systemic myeloid diversity and PD-L1/PD-1 blockade in lung cancer

    EMBO Reports, Vol. 24, Núm. 8

2022

  1. CAR-T Cells for the Treatment of Lung Cancer

    Life, Vol. 12, Núm. 4

  2. Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer

    Cancers, Vol. 14, Núm. 16

  3. Clinical landscape of LAG-3-targeted therapy

    Immuno-Oncology and Technology, Vol. 14

  4. Cutting-Edge CAR Engineering: Beyond T Cells

    Biomedicines, Vol. 10, Núm. 12

  5. Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor

    Cells, Vol. 11, Núm. 15

  6. Immune Profiling Uncovers Memory T-Cell Responses with a Th17 Signature in Cancer Patients with Previous SARS-CoV-2 Infection Followed by mRNA Vaccination

    Cancers, Vol. 14, Núm. 18

  7. Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy

    International Journal of Molecular Sciences, Vol. 23, Núm. 21

2021

  1. Hyperprogressive disease: Main features and key controversies

    International Journal of Molecular Sciences, Vol. 22, Núm. 7

  2. Understanding lag-3 signaling

    International Journal of Molecular Sciences, Vol. 22, Núm. 10